POMDOCTOR LIMITED (POM) Stock

About POMDOCTOR LIMITED

Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed for managing long-term illnesses within the Chinese market. Its primary emphasis is on chronic disease care and pharmaceutical provision, facilitating a digital portal that connects patients with medical professionals and essential medications. Pomdoctor's operations largely encompass both a virtual hospital model and a comprehensive pharmaceutical supply chain, thus linking individual users, pharmacies, distributors, medical experts, and other healthcare stakeholders. This enterprise was established in 2010 and is headquartered in Guangzhou, China.

POMDOCTOR LIMITED is headquartered in CN.

POMDOCTOR LIMITED (POM) stock trades at $1.17 with a market capitalization of $10.05M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.15, reflecting a net loss over the last twelve months, a negative price-to-book of -0.54, reflecting negative shareholders' equity, price-to-sales of 0.07. Over the past 52 weeks the stock has ranged between $0.50 and $115.74, and currently trades 99.0% below its 52-week high.

On profitability, POMDOCTOR LIMITED generates a return on equity (ROE) of 15.65% (not meaningful, as shareholders' equity is negative), return on capital employed of 105.21%, an operating margin of -29.10%, a net profit margin of -53.16%.

Official website: www.7lk.com

POMDOCTOR LIMITED by the numbers, 2019–2025

Between 2019 and 2025 POMDOCTOR LIMITED reported revenue of $185.0M rising to $400.0M, a change of +116.2% across 7 years. Compounded, revenue has grown 22.7% a year over five years, 17.8% over three, 16.6% over the last twelve months. Net profit fell to $-213.0M.

Operating margin went from -34.6% in 2019 to -29.1% in 2025, a gain of 5.5 percentage points. The most recent net margin is -53.16%. On a trailing twelve-month basis to Jun '26, revenue is $346.0M and net profit $-289.0M.

Borrowings rose from $77.0M to $455.0M, cash on hand is $1.9M, cash from operations was $-148.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged 15.3% over five years, and was 46.9% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, -99.2% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

POMDOCTOR LIMITED (POM) — frequently asked questions